Kelsey K. Baker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kelsey K. Baker has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Mary Weber Redman
Fred Hutchinson Cancer Research Center, Seattle, Washington
62 shared publications - Stacey A. Cohen
Fred Hutch Cancer Center, University of Washington, Seattle, WA
62 shared publications - Ming Yu
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA
61 shared publications - William M. Grady
Fred Hutchinson Cancer Center, Seattle, Washington
61 shared publications - Adetunji T. Toriola
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri
60 shared publications - Biljana Gigic
Department of General, Visceral, and Transplantation Surgery Heidelberg University Hospital Heidelberg Germany
60 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by American Society of Hematology in Blood
CD20-directed Autologous CAR T-cell Therapy for Waldenström Macroglobulinemia
No chimeric antigen receptor therapy (CAR-T) is currently approved for WM. This study assessed safety and efficacy of CD20-targeted CAR-T in BTKi-refractory, heavily pre-treated WM patients. With a CR/VGPR rate of 80%, this treatment should be evaluated in larger trials. ClinicalTrials.gov number NCT03277729
- 5 November 2026
- Published by American Society of Hematology in Blood
Open AccessCD20-directed Autologous CAR T-cell Therapy for Waldenström Macroglobulinemia
No chimeric antigen receptor therapy (CAR-T) is currently approved for WM. This study assessed safety and efficacy of CD20-targeted CAR-T in BTKi-refractory, heavily pre-treated WM patients. With a CR/VGPR rate of 80%, this treatment should be evaluated in larger trials. ClinicalTrials.gov number NCT03277729
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 2: Summary patient characteristics for Comparison Set 1
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 2: Summary patient characteristics for Comparison Set 1
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Figure 3: EVL methylation levels of normal colon for patients with no history of adenoma or cancer after initial colonoscopy (left group) and for levels patients with an adenoma or colorectal cancer detected after initial (middle group). Patients with no follow-up colonoscopies (right group) were not included in the analyses for Comparison Set 2. %mEVL=percentage of DNA that is methylated at the EVL locus assayed.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Figure 3: EVL methylation levels of normal colon for patients with no history of adenoma or cancer after initial colonoscopy (left group) and for levels patients with an adenoma or colorectal cancer detected after initial (middle group). Patients with no follow-up colonoscopies (right group) were not included in the analyses for Comparison Set 2. %mEVL=percentage of DNA that is methylated at the EVL locus assayed.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Figure 1. Flowchart of patient selection. * Subjects with hereditary conditions or inflammatory bowel disease (IBD) were excluded. A flowchart showing the selection process for the subjects included in the studies is shown. The primary exclusion criteria that affected subject selection were lack of serial colonoscopy data and lack of tissue from the normal colon
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Figure 1. Flowchart of patient selection. * Subjects with hereditary conditions or inflammatory bowel disease (IBD) were excluded. A flowchart showing the selection process for the subjects included in the studies is shown. The primary exclusion criteria that affected subject selection were lack of serial colonoscopy data and lack of tissue from the normal colon
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Figure 2: Methylation levels of normal colon mucosa in patients with no history of adenoma or cancer ever (group on left) and levels for patients with a history of adenoma(s) or colorectal cancer at initial or a follow-up colonoscopy (group on right) in Comparison Set 1. %mEVL=percentage of DNA that is methylated at the EVL locus assayed.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Figure 2: Methylation levels of normal colon mucosa in patients with no history of adenoma or cancer ever (group on left) and levels for patients with a history of adenoma(s) or colorectal cancer at initial or a follow-up colonoscopy (group on right) in Comparison Set 1. %mEVL=percentage of DNA that is methylated at the EVL locus assayed.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 7 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 7: Summary statistics for methylated EVL measurements in Comparison Set 3
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 7 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 7: Summary statistics for methylated EVL measurements in Comparison Set 3
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 5 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 5: Summary statistics for methylated EVL measurements in Comparison Set 1
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 5 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 5: Summary statistics for methylated EVL measurements in Comparison Set 1
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 4: Summary patient characteristics for Comparison Set 3
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 4: Summary patient characteristics for Comparison Set 3
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 1: Primer/probe sequences used in the duplex mEVL assay
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Table 1: Primer/probe sequences used in the duplex mEVL assay
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Figure 4: Methylation levels of normal colon for patients with no history of adenoma or cancer after initial amongst those at least 4 years of follow-up (left group) and levels for patients with an adenoma or colorectal cancer detected after initial colonoscopy (middle group). Patients without an adenoma or colorectal cancer and less than 4 years of follow-up (right group) were not included in the analyses for Comparison Set 3. %mEVL=percentage of DNA that is methylated at the EVL locus assayed.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
Supplemental Figure 4: Methylation levels of normal colon for patients with no history of adenoma or cancer after initial amongst those at least 4 years of follow-up (left group) and levels for patients with an adenoma or colorectal cancer detected after initial colonoscopy (middle group). Patients without an adenoma or colorectal cancer and less than 4 years of follow-up (right group) were not included in the analyses for Comparison Set 3. %mEVL=percentage of DNA that is methylated at the EVL locus assayed.